The fact that these in vitro characteristics were also evident in an in vivo environment provides stronger evidence for the use of DIM in patients with pancreatic cancer exhibiting overexpression of EGFR and NF-κB [83]. The gene discussed is NFKB1; the disease is familial pancreatic carcinoma.